Employee Stock Ownership Plans as an Exit Strategy for Private Business Owners
March 2017 – An employee stock ownership plan offers business owners an exit strategy that preserves firm continuity, fosters employee commitment, and builds lasting economic value in a community.
Causes and Non-Causes of Drug Shortages
January 2017 – A variety of factors contribute to drug shortages, including quality control concerns in manufacturing and capacity constraints generally.
Estimated Cost of FDA’s Proposed Generic Drug Labeling Rule: Updated for 2017–2024
July 2016 – The FDA’s Proposed Rule to permit generic drug manufacturers to change drug labels would increase generic spending by $5.6 billion in 2017, rising to $8.6 billion in 2024.
Economic Impact of Taxing Professional Services in Illinois
May 2016 — A proposal in Illinois to extend the state sales tax to professional services would have negative economic consequences because a professional services tax is primarily a business-to-business tax.
Payor Strategies to Promote Biosimilar Utilization
April 2016 – Carefully constructed physician incentives from public and private payors could boost biosimilar utilization, benefiting U.S. patients and the health care system as a whole.
Economic Benefits of Increased Home Dialysis Utilization and Innovation
March 2016 – If barriers to home dialysis were removed, the resulting increase in home dialysis utilization would both benefit patients and send strong signals to innovators to develop new technologies.
Understanding the True Causes of the U.S. Methamphetamine Problem
November 2015 – Fighting methamphetamine use in the United States by restricting access to cold and allergy medicines containing pseudoephedrine fails to address core underlying issues: continued demand for meth and an ample foreign supply.
American Association for Justice Misses on “The True Costs of Generic Drug Regulation”
April 2015 – An American Association for Justice report makes both unfounded criticisms of an MGA analysis and false assertions about the impact of the FDA Proposed Rule on generic drug labeling.
The Economic Viability of a U.S. Biosimilars Industry
February 2015 – Because of the expected regulatory framework and economic conditions, a robust U.S. biosimilars market for a broad spectrum of biologic products is unlikely, but biosimilar entry for blockbuster biologic products is viable.
Considerations of the FDA’s Impact on Competition in the Drug Industry
November 2014 – The FDA, within its core mission of ensuring the safety and efficacy of drugs, affects competition in the pharmaceutical industry in important ways.
Obesity in the Medicare Population: Opportunities for Cost Savings
October 2014 – The high rates of obesity among Medicare beneficiaries and the high cost of providing medical care to obese individuals create an enormous financial burden on the federal government.
Strengthening the G20’s Membership
September 2014 – To be legitimate and effective, the G20 needs transparent membership criteria based on economic size and trade activity, adherence to the rule of law, and financial interconnectedness.
Health and Economic Benefits of Weight Loss among Obese U.S. Adults
August 2014 – There is substantial potential savings, nationally and for the Medicare population, from preventing the development of five comorbidities by reducing obesity rates by 10 percent.
Lost Prescription Drug Savings from Use of REMS Programs to Delay Generic Market Entry
July 2014 – If brand drug manufacturers stopped misusing restricted distribution to keep drug samples from generic manufacturers, $5.4 billion in annual drug spending could be saved.
Jobs and Growth Effects of Tax Rate Reductions in Ohio
May 2014 – Proposed tax cuts in Ohio would add jobs, encourage people to move to the state, and increase economic output and after-tax personal income.
Budgetary Impact of Obesity in the United States
May 2014 – The prevalence of obesity nationwide and in Medicare in particular has a substantial federal budgetary impact, but there is evidence that reducing obesity lowers health care spending.
Comparing Economic Impact Estimates of “Reverse Payment” Settlements
February 2014 – Economic studies of “reverse payment” settlements have reached contradictory conclusions about the effect of this type of settlement on consumers, indicating that broad research provides little evidence of the appropriateness of any given settlement.
FDA’s Proposed Generic Drug Labeling Rule: An Economic Assessment
February 2014 – The FDA’s Proposed Rule to allow generic drug makers to make changes to product labels would drastically alter the legal landscape and increase spending on generics by $4 billion per year.
The Long-Term Returns of Obesity Prevention Policies
April 2013 — Obesity prevention policies need longer-term budget impact analyses than the typical 10-year estimates from the Congressional Budget Office.
Macroeconomic Impact of S ESOPs on the U.S. Economy
April 2013 – S corporations that sponsor employee stock ownership plans have a positive impact that benefits not only employee-owners, but also the broader economy.
An Analysis of the Economic Impact of Requiring Prescriptions for Pseudoephedrine Products
March 2013 – Combating methamphetamine by requiring prescriptions for pseudoephedrine medicines would force high social and economic costs on consumers.
An Analysis of the Benefits S ESOPs Provide the U.S. Economy and Workforce
July 2012 – Employee stock ownership plans have been shown to facilitate firm performance and job stability because they foster loyalty to the company among employees.